Tirzepatide emerges a groundbreaking treatment agent for individuals struggling type 2 diabetes. As a dual agonist, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide https://amiegtgf441602.spintheblog.com/40899442/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist